Portaels F, Silva MT, Meyers WM, 2009. Buruli ulcer. Clin Dermatol 27: 291–305.
Mulder AA, Boerma RP, Barogui Y, Zinsou C, Johnson RC, Gbovi J, van der Werf TS, Stienstra Y, 2008. Healthcare seeking behaviour for Buruli ulcer in Benin: a model to capture therapy choice of patients and healthy community members. Trans R Soc Trop Med Hyg 102: 912–920.
Stienstra Y, van der Graaf WT, Asamoa K, van der Werf TS, 2002. Beliefs and attitudes toward Buruli ulcer in Ghana. Am J Trop Med Hyg 67: 207–213.
Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, Awua-Boateng NY, Ampadu EO, Siegmund V, Schouten JP, Adjei O, Bretzel G, van der Werf TS, 2010. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375: 664–672.
Barogui Y, Johnson RC, van der Werf TS, Sopoh G, Dossou A, Dijkstra PU, Stienstra Y, 2009. Functional limitations after surgical or antibiotic treatment for Buruli ulcer in Benin. Am J Trop Med Hyg 81: 82–87.
Stienstra Y, van Roest MH, van Wezel MJ, Wiersma IC, Hospers IC, Dijkstra PU, Johnson RC, Ampadu EO, Gbovi J, Zinsou C, Etuaful S, Klutse EY, van der Graaf WT, van der Werf TS, 2005. Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. Trop Med Int Health 10: 1251–1257.
World Health Organization, 2007. WHO Fact Sheet on Buruli Ulcer, 2012. Geneva: World Health Organization.
Saka B, Landoh DE, Kobara B, Djadou KE, Yaya I, Yekple KB, Piten E, Balaka A, Akakpo S, Kombate K, Mouhari-Toure A, Kanassoua K, Pitche P, 2013. Profile of Buruli ulcer treated at the national reference centre of Togo: a study of 119 cases. Bull Soc Pathol Exot 106: 32–36.
Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, Johnson C, Aubry J, Nuermberger E, Grosset J, 2007. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51: 4029–4035.
Ackumey MM, Kwakye-Maclean C, Ampadu EO, de Savigny D, Weiss MG, 2011. Health services for Buruli ulcer control: lessons from a field study in Ghana. PLoS Negl Trop Dis 5: e1187.
Vouking MZ, Takougang I, Mbam LM, Mbuagbaw L, Tadenfok CN, Tamo CV, 2013. The contribution of community health workers to the control of Buruli ulcer in the Ngoantet area, Cameroon. Pan Afr Med J 16: 63.
Vouking MZ, Tamo VC, Mbuagbaw L, 2013. The impact of community health workers (CHWs) on Buruli ulcer in Sub-Saharan Africa: a systematic review. Pan Afr Med J 15: 19.
Asiedu K, Etuaful S, 1998. Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. Am J Trop Med Hyg 59: 1015–1022.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 1233 | 1036 | 95 |
Full Text Views | 570 | 14 | 0 |
PDF Downloads | 195 | 17 | 0 |
Buruli ulcer (BU) is an infectious skin disease that occurs mainly in West and Central Africa. It can lead to severe disability and stigma because of scarring and contractures. Effective treatment with antibiotics is available, but patients often report to the hospital too late to prevent surgery and the disabling consequences of the disease. In a highly endemic district in Ghana, intensified public health efforts, mainly revolving around training and motivating community-based surveillance volunteers (CBSVs), were implemented. As a result, 70% of cases were reported in the earliest—World Health Organization category I—stage of the disease, potentially minimizing the need for surgery. CBSVs referred more cases in total and more cases in the early stages of the disease than any other source. CBSVs are an important resource in the early detection of BU.
Authors' addresses: Kabiru Mohammed Abass, Justice Abotsi, Samuel Osei Mireku, and William N. Thompson, Buruli Ulcer Clinic, Agogo Presbyterian Hospital, Agogo, Ghana, E-mails: abas@agogopresbyhospital.org, info@agogopresbyhospital.org, inf@agogopresbyhospital.org, and wnat111@yahoo.com. Tjip S. van der Werf, Ymkje Stienstra, and Sandor-Adrian Klis, Department of Internal Medicine–Infectious Diseases, University of Groningen, University Medical Center, Groningen, The Netherlands, E-mails: t.s.van.der.werf@umcg.nl, y.stienstra@umcg.nl, and s.klis@umcg.nl. Richard O. Phillips and Fred S. Sarfo, Internal Medicine, Komfo Anokye Teaching Hospital, Kumasi, Ghana, and School of Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana, E-mails: rodamephillips@gmail.com and stephensarfo78@gmail.com. Kingsley Asiedu, Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland, E-mail: asieduk@who.int.
Portaels F, Silva MT, Meyers WM, 2009. Buruli ulcer. Clin Dermatol 27: 291–305.
Mulder AA, Boerma RP, Barogui Y, Zinsou C, Johnson RC, Gbovi J, van der Werf TS, Stienstra Y, 2008. Healthcare seeking behaviour for Buruli ulcer in Benin: a model to capture therapy choice of patients and healthy community members. Trans R Soc Trop Med Hyg 102: 912–920.
Stienstra Y, van der Graaf WT, Asamoa K, van der Werf TS, 2002. Beliefs and attitudes toward Buruli ulcer in Ghana. Am J Trop Med Hyg 67: 207–213.
Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, Awua-Boateng NY, Ampadu EO, Siegmund V, Schouten JP, Adjei O, Bretzel G, van der Werf TS, 2010. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375: 664–672.
Barogui Y, Johnson RC, van der Werf TS, Sopoh G, Dossou A, Dijkstra PU, Stienstra Y, 2009. Functional limitations after surgical or antibiotic treatment for Buruli ulcer in Benin. Am J Trop Med Hyg 81: 82–87.
Stienstra Y, van Roest MH, van Wezel MJ, Wiersma IC, Hospers IC, Dijkstra PU, Johnson RC, Ampadu EO, Gbovi J, Zinsou C, Etuaful S, Klutse EY, van der Graaf WT, van der Werf TS, 2005. Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. Trop Med Int Health 10: 1251–1257.
World Health Organization, 2007. WHO Fact Sheet on Buruli Ulcer, 2012. Geneva: World Health Organization.
Saka B, Landoh DE, Kobara B, Djadou KE, Yaya I, Yekple KB, Piten E, Balaka A, Akakpo S, Kombate K, Mouhari-Toure A, Kanassoua K, Pitche P, 2013. Profile of Buruli ulcer treated at the national reference centre of Togo: a study of 119 cases. Bull Soc Pathol Exot 106: 32–36.
Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, Johnson C, Aubry J, Nuermberger E, Grosset J, 2007. Promising clinical efficacy of streptomycin-rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51: 4029–4035.
Ackumey MM, Kwakye-Maclean C, Ampadu EO, de Savigny D, Weiss MG, 2011. Health services for Buruli ulcer control: lessons from a field study in Ghana. PLoS Negl Trop Dis 5: e1187.
Vouking MZ, Takougang I, Mbam LM, Mbuagbaw L, Tadenfok CN, Tamo CV, 2013. The contribution of community health workers to the control of Buruli ulcer in the Ngoantet area, Cameroon. Pan Afr Med J 16: 63.
Vouking MZ, Tamo VC, Mbuagbaw L, 2013. The impact of community health workers (CHWs) on Buruli ulcer in Sub-Saharan Africa: a systematic review. Pan Afr Med J 15: 19.
Asiedu K, Etuaful S, 1998. Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. Am J Trop Med Hyg 59: 1015–1022.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 1233 | 1036 | 95 |
Full Text Views | 570 | 14 | 0 |
PDF Downloads | 195 | 17 | 0 |